



Revolutionizing the discovery process of macrocyclic peptides for therapeutic use

Hiroaki Suga

Department of Chemistry, Graduate School of Science, University of Tokyo

Macrocyclic peptides possess a number of pharmacological characteristics distinct from other well-established therapeutic molecular classes, resulting in a versatile drug modality with a unique profile of advantages. Macrocyclic peptides are accessible by not only chemical synthesis but also ribosomal synthesis. Particularly, recent inventions of the genetic code reprogramming integrated with an in vitro display format, referred to as RaPID (Random non-standard Peptides Integrated Discovery) system, have enabled us to screen mass libraries (>1 trillion members) of non-standard peptides containing multiple non-proteinogenic amino acids, giving unique properties of peptides distinct from conventional peptides, e.g. greater proteolytic stability, higher affinity (low nM to sub nM dissociation constants similar to antibodies), and superior pharmacokinetics. The field is rapidly growing evidenced by increasing interests from industrial sectors, including small start-ups as well as mega-pharmas, toward drug development efforts on macrocyclic peptides, which has led to several *de novo* discovered peptides entering clinical trials. This lecture discusses the aforementioned screening technology, the RaPID system, and several showcases of therapeutic potentials of macrocyclic peptides.

References:

- J.M. Rogers, T. Passioura, H. Suga* "Nonproteinogenic deep mutational scanning of linear and cyclic peptides", **Proceedings of the National Academy of Sciences USA** 115 (43) 10959-10964 (2018)
- T. Katoh, H. Suga* "Ribosomal incorporation of consecutive β -amino acids" **Journal of the American Chemical Society** 140, 12159-12167 (2018)
- T. Passioura, W. Liu, D. Dankelmann, T. Higuchi, H. Suga* "Display selection of exotic macrocyclic peptides expressed under a radically reprogrammed 23 amino acid genetic code" **Journal of the American Chemical Society** 140, 11551-11555 (2018)
- A. Kawamura, M. Münzel, T. Kojima, C. Yapp, B. Bhushan, Y. Goto, A. Tumber, T. Katoh, O.N. King, T. Passioura, L.J. Walport, S.B. Hatch, S. Madden, S. Müller, P.E. Brennan, R. Chowdhury, R.J. Hopkinson, H. Suga*, C.J. Schofield "Highly selective inhibition of histone demethylases by de novo macrocyclic peptides" **Nature Communications**, (2017) Apr. 6, 14773.
- H. Yu, P. Dranchak, Z. Li, R. MacArthur, M.S. Munson, N. Mehzabeen, N.J. Baird, K.P. Battalio, D. Ross, S. Lovell, C.K. Carlow, H. Suga*, J. Inglese, "Macrocyclic peptides delineate locked-open inhibition mechanism for microorganism phosphoglycerate mutases" **Nature Communications**, (2017) Apr. 3, 14932.
- S.A. Jongkeess, S. Caner, C. Tysoe, G.D. Brayer, S.G. Withers, H. Suga* "Rapid discovery of potent and selective glycosidase-inhibiting de novo peptides" **Cell Chemical Biology**, (2017) 24, 381-390.
- T. Katoh; I. Wohlgemuth; M. Nagano; M.V. Rodnina; H. Suga "Essential structural elements in tRNA(Pro) for EF-P-mediated alleviation of translation stalling." **Nature communications**, 7, 11657 (2016)
- K. Ito; K. Sakai; Y. Suzuki; N. Ozawa; T. Hatta; T. Natsume; K. Matsumoto; H. Suga "Artificial human Met agonists based on macrocycle scaffolds" **Nature Communications**, 6, 6373 (2015)